Short Interest in Vaxart, Inc. (NASDAQ:VXRT) Increases By 17.0%

Vaxart, Inc. (NASDAQ:VXRT - Get Free Report) was the recipient of a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 13,280,000 shares, an increase of 17.0% from the February 13th total of 11,350,000 shares. Based on an average daily volume of 1,960,000 shares, the days-to-cover ratio is currently 6.8 days. Approximately 6.0% of the shares of the company are short sold.

Vaxart Stock Performance

Vaxart stock traded down $0.05 during trading hours on Friday, reaching $0.52. 2,549,161 shares of the stock were exchanged, compared to its average volume of 2,376,870. Vaxart has a 52-week low of $0.45 and a 52-week high of $1.41. The stock has a market cap of $117.40 million, a P/E ratio of -1.26 and a beta of 1.69. The firm's 50 day moving average is $0.65 and its 200 day moving average is $0.71.

Vaxart (NASDAQ:VXRT - Get Free Report) last posted its quarterly earnings results on Thursday, March 20th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.05. Vaxart had a negative net margin of 431.61% and a negative return on equity of 110.46%. The firm had revenue of $15.19 million during the quarter, compared to analysts' expectations of $15.68 million. Equities research analysts expect that Vaxart will post -0.39 EPS for the current fiscal year.

Remove Ads

Institutional Trading of Vaxart

Several hedge funds have recently modified their holdings of VXRT. Graham Capital Management L.P. raised its position in Vaxart by 155.8% in the fourth quarter. Graham Capital Management L.P. now owns 53,331 shares of the biotechnology company's stock worth $35,000 after acquiring an additional 32,482 shares in the last quarter. Sequoia Financial Advisors LLC increased its holdings in shares of Vaxart by 140.9% in the 4th quarter. Sequoia Financial Advisors LLC now owns 60,213 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 35,213 shares in the last quarter. Invesco Ltd. increased its holdings in shares of Vaxart by 48.6% in the 4th quarter. Invesco Ltd. now owns 75,798 shares of the biotechnology company's stock valued at $50,000 after purchasing an additional 24,803 shares in the last quarter. XTX Topco Ltd lifted its stake in shares of Vaxart by 869.3% in the third quarter. XTX Topco Ltd now owns 136,466 shares of the biotechnology company's stock valued at $116,000 after purchasing an additional 122,387 shares during the period. Finally, Bank of America Corp DE boosted its holdings in Vaxart by 10.8% during the fourth quarter. Bank of America Corp DE now owns 184,447 shares of the biotechnology company's stock worth $122,000 after buying an additional 17,942 shares in the last quarter. 18.05% of the stock is owned by institutional investors and hedge funds.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.